2 October 2009 - Anavex Life Sciences has selected Forenap Pharma EURL as the contract research organisation for Phase One clinical trials of Anavex 2-73.
Anavex 2-73 is the company’s lead Alzheimer’s drug candidate. Anavex 2-73, a sigma-1 receptor agonist, has been shown in pre-clinical testing to be neuroprotective and anti-amnesic.
It is postulated that Anavex 2-73 impacts mitochondrial dysfunction, which is thought by many researchers to be one of the hallmarks of Alzheimer's disease, and may be mitochondrial protective.
This approach focuses on addressing an underlying cause of Alzheimer's disease. Based on recent data, sigma receptors are implicated in oxidative stress, through modulation of calcium signalling via the mitochondria. 18 June 2009 - Anavex Life Sciences has announced the appointment of Dr Herve de Kergrohen as chief executive officer and director. 18 June 2009 - Anavex Life Sciences has announced the appointment of Dr Herve de Kergrohen as chief executive officer and director. De Kergrohen is an accomplished senior executive who has founded and developed numerous life sciences companies throughout his career.
With more than 25 years in senior and executive management positions, de Kergrohen has extensive experience in building and transforming organisations.
